# VERAMORPH, LLC: Preclinical validation of an effective oral fulvestrant product as the future standard of care endocrine therapy for ER+ metastatic breast cancer

**Lab Budget Score:** 55/100

| Field | Value |
|---|---|
| Organization | VERAMORPH, LLC |
| Location | NORWOOD, MA |
| Project | Preclinical validation of an effective oral fulvestrant product as the future standard of care endocrine therapy for ER+ metastatic breast cancer |
| Project number | 4R44CA306533-02 |
| Mechanism | R44 |
| Institute | National Cancer Institute |
| Award | $935,236 |
| Awarded | 2026-09-11 |
| Project period | 2025-09-10 to 2028-08-31 |
| UEI | JZD1YYDDCLP5 |

## Why this score
- Award of $400K or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11457452). Last refreshed: 2026-11-03T18:16:24.961Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.